Table 5.
Quality of Evidence
| Author, Year | Study Design | EPHPP Global Quality Assessment Rating |
|---|---|---|
| Hess, 2007 [21] | Non-Randomized Feasibility | Weak |
| Hess, 2007 [21] | Non-Randomized Feasibility | Weak |
| Wilson, 2008 [27] | Cluster Randomized Control Trial | Weak |
| Holt, 2010 [51] | 2 group Pretest-Posttest | Weak |
| Johnson, 2010 [20] | 2 group Pretest-Posttest | Weak |
| Luque, 2011 [53] | 1 group Posttest only | Weak |
| Sadler, 2011 [29] | Cluster Randomized Control Trial | Weak |
| Victor, 2011 [49, 56] | Cluster Randomized Control Trial | Strong |
| Odedina, 2014 [52] | 1 group Pretest-Posttest | Weak |
| Sadler, 2014 [30] | Cluster Randomized Control Trial | Weak |
| Frencher, 2016 [50] | 2 group Pretest-Posttest | Weak |
| Cole, 2017 [55] | Randomized Control Trial | Weak |
| Victor, 2018 [44] | Cluster Randomized Control Trial | Moderate |
| Victor, 2019 [45] | Cluster Randomized Control Trial | Moderate |